Technical Analysis for IKT - Inhibikase Therapeutics, Inc.

Grade Last Price % Change Price Change
F 5.43 -2.34% -0.13
IKT closed down 2.11 percent on Monday, April 12, 2021, on 18 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical IKT trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -2.34%
Outside Day Range Expansion -2.34%
Narrow Range Bar Range Contraction -4.40%
NR7 Range Contraction -4.40%
Inside Day Range Contraction -4.40%
Fell Below 20 DMA Bearish -4.06%
NR7 Range Contraction -4.06%
Crossed Above 20 DMA Bullish -9.80%
Fell Below 20 DMA Bearish -8.43%
50 DMA Resistance Bearish -12.84%
Older End-of-Day Signals for IKT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 6 hours ago
Down 2 % about 6 hours ago
Down 1% about 6 hours ago
Fell Below Previous Day's Low about 6 hours ago
60 Minute Opening Range Breakdown 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Inhibikase Therapeutics, Inc. Description

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Neurological Disorders Parkinson's Disease Stage Pharmaceutical Psychiatric Diagnosis Dementia Treatment Of Parkinson's Disease Aging Associated Diseases Pyridines Neurodegenerative Disorders Related Disorders Lewy Body Dementia Imatinib

Is IKT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.8
52 Week Low 5.12
Average Volume 90,574
200-Day Moving Average 0.00
50-Day Moving Average 6.53
20-Day Moving Average 5.81
10-Day Moving Average 5.80
Average True Range 0.47
ADX 13.07
+DI 22.09
-DI 19.93
Chandelier Exit (Long, 3 ATRs ) 6.01
Chandelier Exit (Short, 3 ATRs ) 6.52
Upper Bollinger Band 6.50
Lower Bollinger Band 5.12
Percent B (%b) 0.32
BandWidth 23.70
MACD Line -0.22
MACD Signal Line -0.26
MACD Histogram 0.033
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.17
Resistance 3 (R3) 6.20 6.01 6.07
Resistance 2 (R2) 6.01 5.86 6.00 6.04
Resistance 1 (R1) 5.79 5.76 5.69 5.76 6.00
Pivot Point 5.60 5.60 5.56 5.59 5.60
Support 1 (S1) 5.38 5.45 5.29 5.36 5.12
Support 2 (S2) 5.19 5.35 5.18 5.08
Support 3 (S3) 4.97 5.19 5.05
Support 4 (S4) 4.95